<DOC>
	<DOCNO>NCT00177710</DOCNO>
	<brief_summary>The purpose study determine steady state concentration inhale liposomal amphotericin B ( Ambisome® ) lung transplant recipient via aerosolized nebulization .</brief_summary>
	<brief_title>Pharmacokinetic Profile Inhaled Liposomal Amphotericin B Lung Transplant Recipients - Ambisome Study</brief_title>
	<detailed_description>Each subject receive 1 mg/kg/day inhale Ambisome® four day prior BAL ( bronchoalveolar lavage ) procedure . The dosage 1 mg/kg calculate extrapolate dosage 1.6 mg/kg surface area rat lung human lung surface area 60 kg individual . All four dos give presence physician and/or study coordinator . The forty eight subject randomize six subject undergo BAL 1 , 12 , 24 , 48 , 72 , 96 , 120 , 168 hour last dose inhale Liposomal amphotericin B ( AmBisome® ) . A blood sample ( 5 ml ) obtain prior fourth dose study medication day bronchoscopy ( pseudo steady state trough ) . Concentrations amphotericin serum , bronchoalveolar lavage measure pre-specified interval administration liposomal amphotericin B ( AmBisome® ) lung transplant recipient undergo routine bronchoscopy mention earlier . A 5 ml blood sample recover time bronchoscopy purpose determination serum amphotericin B concentration determination serum urea concentration . The bronchoscopy bronchoalveolar lavage subject do part routine transplant care . Subjects follow follow-up result bronchoscopy interval deem necessary transplant pulmonologist . The sample ( blood bronchoalveolar sample ) control principal investigator research project . To protect confidentiality , personal identifier ( i.e. , name , social security number , birth date ) remove ( de-identified ) replace specific code number . The information link code number correspond subject ' identity keep separate , secure location ( ID lab 8th floor Scaife Hall ) . The investigator study keep sample indefinitely . Samples may give investigator outside UPMC may utilize future study infectious disease . If sample give investigator associate study , sample provide without identifier . No genetic test do sample obtain .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Male female lung transplant recipient University Pittsburgh Medical Center ≥ 18 year age eligible study . Single double lung transplant recipient Willing available test center 4 consecutive day Able comprehend complete informed consent Pregnant woman woman capable bearing child , perform urine pregnancy test Nursing mother Subjects hypersensitivity amphotericin deoxycholate liposomal amphotericin Subjects past history bronchospasm associate aerosol drug use Subjects active bacterial viral infection define current use nonprophylactic antibiotic antiviral medication Subjects force expiratory volume 1 second ( FEV1 ) &lt; 30 % predict forced vital capacity ( FVC ) &lt; 30 % receive study medication . Subjects require supplemental oxygen Receipt inhalational intravenous ( IV ) amphotericin B within last 30 day Subjects known fungal infection per Mycoses Study Group ( MSG ) criteria therapy antifungal drug diagnose day bronchoscopy Serum creatinine &gt; 1.9 mg/dl day screen Liver enzymes ALT/AST/alkaline phosphatase great two time normal limit Concurrent intravenous aminoglycoside use Subject fever &gt; 38.2°C Subjects mechanical ventilation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>